|
Gene: HNRNPF |
Gene summary for HNRNPF |
Gene summary. |
Gene information | Species | Human | Gene symbol | HNRNPF | Gene ID | 3185 |
Gene name | heterogeneous nuclear ribonucleoprotein F | |
Gene Alias | HNRPF | |
Cytomap | 10q11.21 | |
Gene Type | protein-coding | GO ID | GO:0000375 | UniProtAcc | A0A024R7T3 |
Top |
Malignant transformation analysis |
Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
Malignant transformation involving gene list. |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
3185 | HNRNPF | GSM4909282 | Human | Breast | IDC | 3.76e-05 | 3.35e-01 | -0.0288 |
3185 | HNRNPF | GSM4909285 | Human | Breast | IDC | 3.04e-12 | 4.23e-01 | 0.21 |
3185 | HNRNPF | GSM4909286 | Human | Breast | IDC | 9.55e-03 | 2.88e-02 | 0.1081 |
3185 | HNRNPF | GSM4909290 | Human | Breast | IDC | 4.12e-05 | 3.69e-01 | 0.2096 |
3185 | HNRNPF | GSM4909293 | Human | Breast | IDC | 2.59e-02 | -6.10e-02 | 0.1581 |
3185 | HNRNPF | GSM4909294 | Human | Breast | IDC | 1.01e-05 | 4.92e-02 | 0.2022 |
3185 | HNRNPF | GSM4909296 | Human | Breast | IDC | 3.52e-15 | -2.90e-01 | 0.1524 |
3185 | HNRNPF | GSM4909297 | Human | Breast | IDC | 1.31e-19 | 1.48e-02 | 0.1517 |
3185 | HNRNPF | GSM4909301 | Human | Breast | IDC | 6.06e-03 | -1.75e-01 | 0.1577 |
3185 | HNRNPF | GSM4909309 | Human | Breast | IDC | 1.10e-04 | -3.42e-01 | 0.0483 |
3185 | HNRNPF | GSM4909311 | Human | Breast | IDC | 2.11e-37 | -3.27e-01 | 0.1534 |
3185 | HNRNPF | GSM4909312 | Human | Breast | IDC | 1.49e-22 | 2.36e-01 | 0.1552 |
3185 | HNRNPF | GSM4909318 | Human | Breast | IDC | 2.44e-03 | 3.69e-01 | 0.2031 |
3185 | HNRNPF | GSM4909319 | Human | Breast | IDC | 1.01e-48 | -4.49e-01 | 0.1563 |
3185 | HNRNPF | GSM4909320 | Human | Breast | IDC | 1.59e-09 | -5.93e-01 | 0.1575 |
3185 | HNRNPF | GSM4909321 | Human | Breast | IDC | 7.56e-19 | -8.83e-02 | 0.1559 |
3185 | HNRNPF | brca1 | Human | Breast | Precancer | 5.62e-03 | 2.75e-01 | -0.0338 |
3185 | HNRNPF | brca2 | Human | Breast | Precancer | 8.48e-05 | 3.46e-01 | -0.024 |
3185 | HNRNPF | brca3 | Human | Breast | Precancer | 5.62e-04 | 3.26e-01 | -0.0263 |
3185 | HNRNPF | brca10 | Human | Breast | Precancer | 1.24e-11 | -5.02e-01 | -0.0029 |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Transcriptomic changes along malignancy continuum. |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
Figure of enriched GO biological processes. |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | |
Colorectum | SER | |
Colorectum | MSS | |
Colorectum | MSI-H | |
Colorectum | FAP |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
Enriched GO biological processes. |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00083809 | Breast | Precancer | RNA splicing | 65/1080 | 434/18723 | 1.27e-12 | 2.53e-10 | 65 |
GO:00434849 | Breast | Precancer | regulation of RNA splicing | 34/1080 | 148/18723 | 2.66e-12 | 4.75e-10 | 34 |
GO:00003759 | Breast | Precancer | RNA splicing, via transesterification reactions | 52/1080 | 324/18723 | 1.74e-11 | 2.22e-09 | 52 |
GO:00003779 | Breast | Precancer | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:00003989 | Breast | Precancer | mRNA splicing, via spliceosome | 51/1080 | 320/18723 | 3.55e-11 | 4.04e-09 | 51 |
GO:000838014 | Breast | IDC | RNA splicing | 73/1434 | 434/18723 | 1.27e-10 | 1.57e-08 | 73 |
GO:004348414 | Breast | IDC | regulation of RNA splicing | 36/1434 | 148/18723 | 3.32e-10 | 3.77e-08 | 36 |
GO:000037514 | Breast | IDC | RNA splicing, via transesterification reactions | 58/1434 | 324/18723 | 9.44e-10 | 9.58e-08 | 58 |
GO:000037714 | Breast | IDC | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000039814 | Breast | IDC | mRNA splicing, via spliceosome | 57/1434 | 320/18723 | 1.60e-09 | 1.49e-07 | 57 |
GO:000838024 | Breast | DCIS | RNA splicing | 73/1390 | 434/18723 | 3.05e-11 | 5.08e-09 | 73 |
GO:004348424 | Breast | DCIS | regulation of RNA splicing | 36/1390 | 148/18723 | 1.40e-10 | 1.69e-08 | 36 |
GO:000037524 | Breast | DCIS | RNA splicing, via transesterification reactions | 58/1390 | 324/18723 | 2.89e-10 | 3.34e-08 | 58 |
GO:000037724 | Breast | DCIS | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:000039824 | Breast | DCIS | mRNA splicing, via spliceosome | 57/1390 | 320/18723 | 5.01e-10 | 5.35e-08 | 57 |
GO:0008380 | Colorectum | AD | RNA splicing | 169/3918 | 434/18723 | 3.59e-18 | 2.04e-15 | 169 |
GO:0000377 | Colorectum | AD | RNA splicing, via transesterification reactions with bulged adenosine as nucleophile | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000398 | Colorectum | AD | mRNA splicing, via spliceosome | 130/3918 | 320/18723 | 5.88e-16 | 2.16e-13 | 130 |
GO:0000375 | Colorectum | AD | RNA splicing, via transesterification reactions | 131/3918 | 324/18723 | 7.11e-16 | 2.22e-13 | 131 |
GO:0043484 | Colorectum | AD | regulation of RNA splicing | 70/3918 | 148/18723 | 6.47e-13 | 1.16e-10 | 70 |
Page: 1 2 3 4 5 6 |
Enriched KEGG pathways. |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
Annotation of somatic variants for genes involved in malignant transformation |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
HNRNPF | SNV | Missense_Mutation | novel | c.1226A>C | p.Asn409Thr | p.N409T | P52597 | protein_coding | tolerated(0.39) | benign(0.024) | TCGA-EO-A22R-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HNRNPF | SNV | Missense_Mutation | novel | c.904N>A | p.Glu302Lys | p.E302K | P52597 | protein_coding | tolerated(0.12) | benign(0.246) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HNRNPF | SNV | Missense_Mutation | novel | c.6G>T | p.Met2Ile | p.M2I | P52597 | protein_coding | tolerated(0.11) | probably_damaging(0.924) | TCGA-DD-AADF-01 | Liver | liver hepatocellular carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
HNRNPF | SNV | Missense_Mutation | novel | c.279N>A | p.Met93Ile | p.M93I | P52597 | protein_coding | deleterious(0.01) | benign(0.135) | TCGA-WQ-A9G7-01 | Liver | liver hepatocellular carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
HNRNPF | SNV | Missense_Mutation | c.528N>G | p.Ile176Met | p.I176M | P52597 | protein_coding | tolerated(0.08) | possibly_damaging(0.734) | TCGA-44-7669-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Chemotherapy | alimta | PD | |
HNRNPF | SNV | Missense_Mutation | rs772316006 | c.203N>C | p.Lys68Thr | p.K68T | P52597 | protein_coding | tolerated(0.08) | benign(0.436) | TCGA-44-A4SS-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
HNRNPF | SNV | Missense_Mutation | novel | c.18N>T | p.Glu6Asp | p.E6D | P52597 | protein_coding | tolerated(0.12) | benign(0.014) | TCGA-49-4486-01 | Lung | lung adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
HNRNPF | SNV | Missense_Mutation | c.617G>C | p.Arg206Pro | p.R206P | P52597 | protein_coding | deleterious(0.04) | benign(0.027) | TCGA-55-8302-01 | Lung | lung adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
HNRNPF | SNV | Missense_Mutation | novel | c.716N>T | p.Gly239Val | p.G239V | P52597 | protein_coding | deleterious(0.02) | possibly_damaging(0.53) | TCGA-64-5781-01 | Lung | lung adenocarcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
HNRNPF | SNV | Missense_Mutation | novel | c.482C>T | p.Ser161Leu | p.S161L | P52597 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-86-8056-01 | Lung | lung adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Page: 1 2 3 4 5 6 |
Top |
Related drugs of malignant transformation related genes |
Identification of chemicals and drugs interact with genes involved in malignant transfromation |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |